The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Using immunotherapy to treat anal cancer
Sheela Rao, MBBS, FRCP, MD (Res), Royal Marsden Hospital, London, UK, discusses research into immunotherapy for anal cancer. Trials researching the effects of chemoradiotherapy alongside immunotherapy are currently ongoing, and a trial is presently investigating this in an adjuvant setting following chemoradiation. In the advanced setting, there has been a single negative study; however, two large Phase III trials will be reporting results in 2024. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
